Avai Bio 3Q 2026: Revenue $0, EPS ($0.00) — 10-Q Summary
Avai Bio reported no revenue for 3Q 2026, with a net loss of $253,240, a 44% improvement from the prior year. Operating expenses decreased 36% and other expenses fell to zero. The company acquired the Lifestyle Wellness Assessment API for $58,600. Operating cash use declined $122,313 year over year to $489,577 in the six months ended September 30, 2026.
